Shares Questcor Corp. (NASDAQ: QCOR) tumbled on Monday after analysts at Favus Institutional Research cut their rating on the stock to “sell” from “buy”, citing concerns over the company’s fiscal first quarter results. In its note to clients, Favus said that should the company fails in meeting or misses Q1 results then it would be not easy to gauge whether the slowdown is due to “external reimbursement pushback or QCOR’s internal reorganization of reimbursement process.” The research firm said that sales could feel the pressure as bulk orders for the Achtar Gel (repository corticotropin injection), which is its primary product, were filled in late fiscal fourth quarter.
Continue reading Major Movers on April 8; QCOR, NIHD, BCRX, GOL, LUFK, EPL